IMV Inc. completes public offering of units for proceeds of approximately US$25 million

Date Closed

July 19, 2021

Lead Office

Québec City


25.00 Million USD

On July 20, 2021, IMV Inc. closed an underwritten public offering of 14,285,714 units, for total gross proceeds of US$25 million. IMV intends to use the net proceeds of the offering to further several of its clinical developments and for general corporate purposes.

IMV is a biopharmaceutical company based in Dartmouth, Nova Scotia. It is focused on creating more effective immunotherapies for cancer and other diseases.

McCarthy Tétrault advised IMV with a team led by Philippe Leclerc that included Myreille Gilbert and Mireille Trottier (Securities), and Marie-Soleil Landry and Geneviève Favreau (Tax).